Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RESMED INCRMD · Entity 2692 | Director · Chairman and CEO | October 07, 2026 | October 08, 2026 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RESMED INC
Report date October 07, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 479,803 |
Ending reported balance
After 2026-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-07 · Exercise / conversion · Acquired 4,991 · Balance 484,794 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Row 2 · 2026-10-07 · Sale · Disposed 4,991 · Balance 479,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. |
| ResMed Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $146.34 · Expires 2026-11-21 | Direct | 4,993 |
Reported balance
After 2026-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-07 · Exercise / conversion · Disposed 4,991 · Balance 4,993 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3: Represents date options first become exercisable. Options vest 1/3 per year |
| ResMed Common StockSEC Table I · non-derivative | IndirectLisette and Michael Farrell Family Trust | 2,090 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,090 |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price.
F3: Represents date options first become exercisable. Options vest 1/3 per year
ZIMMER BIOMET HOLDINGS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85 | Direct | 20,073.731 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 417.363 · Balance 20,073.731 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2025 Filed Nov 11, 2025 00:07 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 983 | $101.64 | $99,912.12 |
DisclosureSEC source: 0000943819-25-000095 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 468,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · balance_after: Includes 74.3412 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 15:03 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000086 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,011 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 15:03 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,009 | $282.85 | $2,265,332.03 |
DisclosureSEC source: 0000943819-25-000086 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 467,792 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $280.95 - $283.90. The price reported above reflects the weighted average sale price. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 15:03 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0000943819-25-000086 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 475,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 21:16 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 382.263 | $0.00 Strike: $98.10 | $0.00 |
DisclosureSEC source: 0001485164-25-000007 · form4-10022025_091057.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,318.948 Underlying: Common Stock · 382.263 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 42.678 phantom stock units accrued on July 31, 2025 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:10 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000061 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,020 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:10 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,009 | $278.14 | $2,227,590.42 |
DisclosureSEC source: 0000943819-25-000061 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 467,792 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $275.27 - $279.57. The price reported above reflects the weighted average sale price. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:10 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0000943819-25-000061 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 475,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 18:28 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 12,289 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000039 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467,792 F1 · kind: Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest1/3 each year on the anniversary of the grant. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 14:45 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000038 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,029 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 14:45 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,009 | $279.48 | $2,238,378.55 |
DisclosureSEC source: 0000943819-25-000038 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,503 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $277.76 - $282.66. The price reported above reflects the weighted average sale price. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 14:45 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0000943819-25-000038 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 12:37 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000027 · form4.xml · derivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,038 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 12:37 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,009 | $256.72 | $2,056,076.09 |
DisclosureSEC source: 0000943819-25-000027 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,503 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $255.6 - $258.22. The price reported above reflects the weighted average sale price. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 12:37 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0000943819-25-000027 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:36 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 466.469 | $0.00 Strike: $91.11 | $0.00 |
DisclosureSEC source: 0001062993-25-012469 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,894.007 Underlying: Common Stock · 466.469 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 22:35 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000019 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,047 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 22:35 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,009 | $251.21 | $2,011,909.65 |
DisclosureSEC source: 0000943819-25-000019 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,503 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $248.57 - $252.31. The price reported above reflects the weighted average sale price. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 22:35 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0000943819-25-000019 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:21 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,404.798 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-010736 · form4.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,239.726 Underlying: Common Stock · 1,404.798 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:21 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 810.46 | $0.00 Strike: $92.54 | $0.00 |
DisclosureSEC source: 0001062993-25-010736 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,427.538 Underlying: Common Stock · 810.46 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. (the "Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: These units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: These units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 36.578 phantom stock units accrued on April 30, 2025 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| May 07, 2025 Filed May 9, 2025 15:01 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-25-013796 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,056 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F4 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| May 07, 2025 Filed May 9, 2025 15:01 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,009 | $243.23 | $1,948,003.44 |
DisclosureSEC source: 0001127602-25-013796 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,503 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $241.50 - $245.09. The price reported above reflects the weighted average sale price. Read SEC document |
| May 07, 2025 Filed May 9, 2025 15:01 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0001127602-25-013796 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · balance_after: Includes 30.3711 shares of ResMed stock purchased on April 30, 2025, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 14:52 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-25-011839 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,065 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 14:52 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,009 | $209.85 | $1,680,699.06 |
DisclosureSEC source: 0001127602-25-011839 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,472 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $200.18 - $218.54. The price reported above reflects the weighted average sale price. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 14:52 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0001127602-25-011839 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:40 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 288.863 | $0.00 Strike: $112.51 | $0.00 |
DisclosureSEC source: 0001062993-25-006908 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,580.5 Underlying: Common Stock · 288.863 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 32.604 phantom stock units accrued on January 31, 2025 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 15:04 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-25-008958 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,074 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 15:04 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,009 | $229.20 | $1,835,692.43 |
DisclosureSEC source: 0001127602-25-008958 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,472 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $223.64 - $232.39. The price reported above reflects the weighted average sale price. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 15:04 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0001127602-25-008958 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 17:54 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-25-004041 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,083 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 17:54 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,009 | $236.77 | $1,896,306.95 |
DisclosureSEC source: 0001127602-25-004041 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,472 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $235.74 - $238.67 The price reported above reflects the weighted average sale price. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 17:54 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0001127602-25-004041 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:08 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 307.386 | $0.00 Strike: $105.73 | $0.00 |
DisclosureSEC source: 0001062993-25-000138 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,259.033 Underlying: Common Stock · 307.386 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 33.106 phantom stock units accrued on October 31, 2024 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| November 27, 2024 Filed Nov 27, 2024 20:19 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $249.67 | $499,330.00 |
DisclosureSEC source: 0001127602-24-028165 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Lisette and Michael Farrell Foundation Disclosed balance after: 0 Read SEC document |
| November 27, 2024 Filed Nov 27, 2024 20:19 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028165 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Lisette and Michael Farrell Foundation Disclosed balance after: 2,000 F2 · kind: Gift of shares transferred from The Lisette and Michael Farrell Family Trust, Mr. Farrell retains dispositive power over the gifted shares. Read SEC document |
| November 27, 2024 Filed Nov 27, 2024 20:19 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028165 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Lisette and Michael Farrell Family Trust Disclosed balance after: 2,090 F1 · kind: Gift of shares transferred to The Lisette and Michael Farrell Family Foundation, Mr. Farrell retains dispositive power over remaining shares. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 20:19 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 33,036 | $249.56 Strike: $249.56 | $8,244,464.16 |
DisclosureSEC source: 0001127602-24-028165 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,036 Underlying: ResMed Common Stock · 33,036 shares Expires 2031-11-25 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:37 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 3,452.9 | $252.38 | $871,442.90 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · nonDerivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,472 F7 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:37 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 2,226.863 | $252.38 | $562,015.68 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,925 F6 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:37 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 3,101.376 | $252.38 | $782,725.27 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,152 F5 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 22:37 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 14,683 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · derivative · entry 7 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 14,683 shares Expires 2024-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. F9 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 22:37 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 14,683 | $246.26 | $3,615,820.90 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,254 F3 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $244.74 - $248.38 The price reported above reflects the weighted average sale price. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 22:37 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 14,683 | $84.98 | $1,247,761.34 |
DisclosureSEC source: 0001127602-24-027086 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. F2 · balance_after: Includes 84.129 shares of ResMed stock purchased on October 31, 2024, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 17:44 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 14,683 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001127602-24-025362 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,683 Underlying: ResMed Common Stock · 14,683 shares Expires 2024-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 17:44 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 14,683 | $231.91 | $3,405,206.48 |
DisclosureSEC source: 0001127602-24-025362 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,169 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $230.66 - $234.70 The price reported above reflects the weighted average sale price. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 17:44 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 14,683 | $84.98 | $1,247,761.34 |
DisclosureSEC source: 0001127602-24-025362 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:22 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 301.596 | $0.00 Strike: $107.76 | $0.00 |
DisclosureSEC source: 0001062993-24-017257 · form4.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,918.541 Underlying: Common Stock · 301.596 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 30.724 phantom stock units accrued on July 31, 2024 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 01:11 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 14,683 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001127602-24-023757 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,366 Underlying: ResMed Common Stock · 14,683 shares Expires 2024-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.